Clinical Trial

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-16; most recent amendment 2025-09-10.
Trial Details
NCT Number NCT05745623
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
Enrollment 70 participants
Start Date 2022-12-27
Primary Completion 2027-12-25 (estimated)
Study Completion 2028-12-25 (estimated)
Updated on ClinicalTrials.gov 2025-09-11